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Abstract
Demineralized bone matrices (DBMs) have been used in a wide variety of clinical 
applications involving bone repair. Ideally, DBMs should provide osteoinductive and 
osteoconductive properties, while offering versatile handling capabilities. With this, 
a novel fiber technology, LifeNet Health-Moldable Demineralized Fibers (L-MDF), 
was recently developed. Human cortical bone was milled and demineralized to 
produce L-MDF. Subsequently, the fibers were lyophilized and terminally steril-
ized using low-dose and low-temperature gamma irradiation. Using L929 mouse 
fibroblasts, L-MDF underwent cytotoxicity testing to confirm lack of a cytotoxic 
response. An alamarBlue assay and scanning electron microscopy demonstrated 
L-MDF supported the cellular function and attachment of bone-marrow mesen-
chymal stem cells (BM-MSCs). Using an enzyme-linked immunosorbent assay, 
L-MDF demonstrated BMP-2 and 7 levels similar to those reported in the literature. 
In vivo data from an athymic mouse model implanted with L-MDF demonstrated the 
formation of new bone elements and blood vessels. This study showed that L-MDF 
have the necessary characteristics of a bone void filler to treat osseous defects.
Keywords: demineralized bone matrix, osteoinductive, osteoconductive, allograft, 
growth factors, bone formation
1. Introduction
Bone voids may occur due to trauma, surgery, tumor resections, or other fac-
tors. For decades, surgeons have used bone grafting to treat a wide variety of bone 
defects. Bone grafts may contain up to three of the vital properties necessary for 
bone formation: osteoconductivity, osteoinductivity, and osteogenicity [1]. The 
property of osteoconductivity describes the way the graft acts as a scaffold on which 
host cells can attach and proliferate, leading to osseointegration. Osteoinductivity, 
on the other hand, describes the cellular signaling potential of a graft. Whether 
endogenous or recombinant, specific growth factors, such as bone morphogenetic 
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protein 2 (BMP-2), attract host cells to a graft and encourage mesenchymal stem cells 
to differentiate into lineage-committed bone cells. Finally, osteogenicity describes 
the ability of a bone graft to form bone matrix directly, which can only happen when 
live cells capable of producing bone matrix are contained within the graft. Bone graft 
options may contain varying amounts of these properties and are chosen based on the 
characteristics that the patient needs in order to achieve bone fusion. There are several 
graft options available, including autograft, synthetic bone substitutes, and allografts.
Autologous bone is harvested from the site of surgery in the patient or a second 
site, such as the iliac crest. It is still considered the gold standard by many surgeons 
because it can theoretically provide all three vital properties for bone formation, 
does not provoke an immune response, and has a long history of use. However, the 
use of autograft bone is associated with several disadvantages such as donor site 
morbidity, insufficient supply, and variable quality [2, 3]. Up to 30% of patients 
experience significant donor site morbidity as well as infection risk, increased 
operative time, blood loss, and the potential for arterial and nerve injury [4]. 
Additionally, autograft is limited, and the quality may be poor depending on the 
patient’s health. For example, diabetes, low bone mass, and smoking can all increase 
the risk of fusion failure as well as intraoperative complications [5].
Synthetic bone substitutes are designed with the goal of mimicking the natural 
properties of human bone. They can be comprised of a variety of materials including 
but not limited to, ceramics, cements, and bioactive glass. These grafts are generally 
biocompatible, osteoconductive, and may be mechanically similar to bone [6, 7]. This 
category of graft has typically been manufactured to contain porosity similar to bone, 
but may lack other desirable surface properties, such as hydrophilicity or a rough 
surface on which cells can attach. Synthetic bone substitutes have gained popular-
ity due to reduced cost and ready availability; however, they may have mismatched 
resorption rates compared to bone and generally lack osteogenic and osteoinductive 
properties [8]. Some synthetics, such as recombinant human BMP-2, depend almost 
solely upon osteoinductivity and often result in rapid bone formation. However, 
several studies indicate substantial side effects, including osteolysis, heterotopic bone 
formation, and swelling/edema [9–11]. While synthetics have improved over the 
last few decades, mimicking natural bone has proven difficult, and allografts, being 
natural bone, have continued to be a reliable source of grafting material.
Allograft bone is obtained from deceased human donors and has a long his-
tory of use. It is readily available in a variety of forms, shapes, and sizes provid-
ing surgeons with several graft options suitable for various procedures [12–14]. 
Allografts can provide up to all three properties necessary for bone formation. For 
example, mineralized bone allografts have similar osteoconductive properties to 
autograft while avoiding complications such as donor site morbidity [15]. Some 
mineralized grafts have been processed to increase desirable characteristics such as 
increased surface area on which cells can attach as well as increased coefficient of 
friction to prevent the graft from shifting once implanted. Other allografts, such as 
demineralized bone matrix (DBM) are both osteoconductive and osteoinductive. 
To produce DBMs, acid demineralization is used to remove a portion of the mineral 
component of bone, thus exposing the active signaling proteins necessary to induce 
new bone formation. The ability of DBMs to facilitate bone healing was demon-
strated in clinical applications as early as 1889 when Dr. Nicholas Senn reported 
using demineralized bone as a vehicle for antiseptics to treat patients with osteo-
myelitis [16]. However, it was not until 1965, when Dr. Marshall Urist characterized 
specific proteins trapped within the bone matrix, that it was understood that bone 
morphogenetic proteins (BMPs) contributed to the osteoinductive property of 
DBMs [17]. Since the discovery of BMPs, other proteins, such as those associated 
with angiogenesis, have also been found to contribute to the process of bone healing 
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and regeneration [18]. In addition to containing active signaling proteins, optimal 
surface characteristics of DBMs are essential for supporting cellular attachment and 
proliferation. For example, it is crucial to provide enough space for blood vessel for-
mation and for the patient’s own cells to migrate into and proliferate on the scaffold 
[19, 20]. Therefore, some allograft processors work to maintain ideal porosity for 
cell migration and angiogenesis. Other processes are designed to create a hospitable 
topography for cell attachment and proliferation as well as to enhance handling 
characteristics to facilitate implantation and mitigate migration.
DBMs are available in varying forms, including powders, putty, strips, and 
moldable paste. These grafts often contain carriers such as glycerol, starch, or hyal-
uronic acid to improve handling. Without a carrier, bone grafts may be difficult to 
implant in the desired area, or may drift away from the area during surgical irriga-
tion or exposure to blood. However, despite improved handling characteristics, it 
has been reported that some carriers may inhibit osteoinductive potential [21]. In 
addition, a carrier dilutes the bone concentration and may easily elute from the sur-
gical site, effectively reducing the implant volume. With these limitations in mind, 
a novel DBM with unique fiber technology was recently developed as described in 
Section 2. These fibers (Figure 1) are composed solely of demineralized cortical 
bone and are designed to provide surface features conducive for cellular attachment 
and easily moldable handling characteristics, all without the addition of a carrier. 
The purpose of this chapter is to present original research, detailing the composi-
tion, osteoinductive nature, cell attachment properties and endogenous bone 
growth factor content of these bone fibers through in vivo and in vitro test methods.
2. Methodology
2.1 Fiber generation
The fibers described here are referred to as L-MDF (LifeNet Health-Moldable 
Demineralized Fibers, LifeNet Health, Virginia Beach, VA and clinically available 
as part of PliaFX® and OraGRAFT® Prime brands). The particular fibers studied 
below were prepared from human cortical long bones that were aseptically recov-
ered from donors, debrided, and disassociated from marrow and trabecular bone. 
The resulting tissue was processed by a proprietary computer numerical controlled-
milling method (CNC-milled) into long fibers and disinfected using a proprietary 
process. The fibers were then demineralized using proprietary procedures. 
Following demineralization, fiber samples were taken to quantify residual calcium 
levels (average 1.7%) using a calcium reagent kit (Eagle Diagnostics, Cedar Hill, 
Figure 1. 
Rehydrated moldable demineralized fibers.
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TX). The demineralized fibers were then freeze-dried, placed in final packaging, 
and treated via low-dose, low-temperature gamma irradiation, at a level necessary 
to achieve a sterility assurance level (SAL) of 10−6.
2.2 Cytotoxicity testing of L-MDF using L929 mouse fibroblasts
The cytotoxic potential of L-MDF were quantitatively evaluated by the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using L929 
mouse fibroblasts. Three samples of 2.5 cc from each of the six donors (n = 18) 
were rehydrated with 5 mL sterile saline (0.99% w/v sodium chloride in water). 
Sample extracts were prepared by incubating 0.2 g of each sample with 1 mL of 
extraction medium (Minimum Essential Medium supplemented with 10% v/v 
fetal bovine serum, 100 U mL−1 penicillin, 100 μg mL−1 streptomycin, and 2 mM 
l-glutamine) for 24 ± 2 h at 37 ± 1°C. Negative and positive controls were prepared 
similarly. Extraction medium alone was used as an untreated control “extract” for 
quantitative comparison of results. L929 mouse fibroblasts were cultured in 96-well 
microplates to half-confluency and subsequently exposed to 100 μL of sample or 
control extracts for 24–26 h at 37 ± 1°C. Following extract exposure, cell viability of 
each well was measured using a MTT assay. The average results for each group were 
normalized to the untreated control to determine a percent viability. Per ISO 10993-
5:2009, percent viability less than 70% indicates a cytotoxic effect.
2.3 In vitro metabolic activity of seeded bone marrow-mesenchymal stem cells
Human bone marrow-derived mesenchymal stem cells (BM-MSCs) seeded on 
L-MDF were measured for metabolic activity using an alamarBlue® assay (Bio-Rad, 
Raleigh, NC) over the course of 7 days. L-MDF from six donors were placed in tripli-
cate in low-attachment 24-well cell culture plates at a density of 13.1 mg of fiber per 
cm2 and seeded with BM-MSCs at 62,500 cells per well on day 0. BM-MSCs without 
fibers served as the control. After 2–4 h in culture, 1 mL of complete media was 
added to each well, followed by incubation at 37°C. Samples remained in the incuba-
tor until specific time points designated for analysis, at which point media was 
replaced. The metabolic activity of cells adhered to the fibers was measured after 1, 
4 and 7 days in culture. At each time point media was aspirated and replaced with 
1 mL of 10% alamarBlue reagent and incubated for an average of 2 h at 37°C. The 
solution was collected from each sample, centrifuged to pellet any debris, and mea-
sured in a 96-well plate at 544 nm excitation/592 nm emission. Fluorescence was 
recorded using relative fluorescence units (RFUs), and values were normalized to 
its time-matched control. A one-way ANOVA in conjunction with a Tukey post-hoc 
was used to determine differences in metabolic activity over time.
2.4 In vitro cellular attachment of seeded bone marrow-mesenchymal cells
Scanning electron microscopy (SEM) was used to qualitatively evaluate the attach-
ment and morphology of cells seeded on four L-MDF samples (25 ± 1 mg) at 0.5–1 h, 
1 and 7 days in culture. The fibers were placed in separate glass scintillation vials 
with 1 mL of complete media and incubated at 37°C. Following incubation, excess 
media was aspirated and BM-MSCs were seeded at 100,000 per cells per vial. At each 
time point, corresponding vials were removed from the incubator, excess media was 
removed, and 3 mL of 2.5% glutaraldehyde in cacodylate buffer was added to fix the 
samples. Cell-seeded samples were rinsed in 0.1 M cacodylate buffer, incubated in 
1% osmium tetroxide for 60 min, and then dehydrated in a series of ethanol solutions 
increasing in concentration up to 100%. Samples were then dried via evaporation of a 
chemical drying agent, hexamethyldisilazane (HMDS). Prior to imaging, all samples 
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were sputter coated in gold palladium for 200 s at 60 mA, then secured to a holder that 
was placed inside a vacuum-sealed imaging chamber. Samples were then imaged at a 
magnification 3000× using a Zeiss Gemini HD Scanning Electron Microscope.
2.5 In vitro growth factor analysis
L-MDF were analyzed for the presence of BMP-2 and BMP-7 using an enzyme-
linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis MN). L-MDF 
from six donors were weighed (30 ± 10 mg per donor) and placed in microcentri-
fuge tubes. Samples were then rehydrated with 5 μL of Dulbecco’s Modified Eagle 
Medium (DMEM) per milligram of fiber, followed by the addition of purified col-
lagenase (14.47 Units/mg of fiber). The samples were digested at 37°C with constant 
mixing for 16–18 h. Digestion solutions were centrifuged to remove remaining 
undigested components and the supernatants were collected for testing. The result-
ing solutions were analyzed for BMP content in triplicate using an ELISA assay. The 
measured BMP content was averaged across all six donors and results were reported 
in ng protein/g of demineralized fibers.
2.6 In vivo osteoinductive potential (OI)
The osteoinductive potential of L-MDF was evaluated using an in vivo athymic 
mouse model at NAMSA (Northwood, Ohio) following American Society for 
Testing and Materials (ASTM) F-2529 guidelines. Four 20–25 mg replicates of 
L-MDF were rehydrated with 100–150 μL of sterile 0.9% w/v sodium chloride and 
loaded into 0.3 cc sterile syringes. Samples were then compressed to remove excess 
solution, and implanted bi-laterally between the biceps femoris and superficial glu-
teal muscle of athymic mice. All mice were euthanized 5 weeks post-implantation 
by carbon dioxide inhalation. Explants were fixed with 10% formalin and bisected 
along the long axis. Bisects of each explant were paraffin embedded, and three 
slides were generated each with 4–6 μm-thick tissue sections. Once stained with 
hematoxylin and eosin (H&E), slides were evaluated by a blinded pathologist. The 
presence of cartilage, chondroblasts, chondrocytes, osteoblasts, osteocytes, osteoid, 
newly formed lamellar bone, and bone marrow were evaluated as new bone ele-
ments as they are indicators of endochondral bone formation process.
3. Results
3.1 Cytotoxicity
Cytotoxicity assay results showed that negative and positive controls behaved as 
expected (i.e., percent viability ≥70% for the negative control groups and <70% for 
the positive control groups). The average percent viability for negative and positive 
controls were 94 and 4%, respectively. The average percent viability of L-MDF 
(91%) was above the 70% threshold, and thus, based on the criteria of the protocol 
and ISO 10993-5 guidelines, L-MDF are considered to be non-cytotoxic.
3.2  L-MDF supports attachment and sustained metabolic activity of bone 
marrow-mesenchymal stem cells
Overall, the cellular activity of the BM-MSCs was shown to significantly increase 
over the course of the 7 day investigation. The results indicated that cells seeded 
on L-MDF showed a significant increase in proliferation between days 4 (51.3 ± 1.2 
RFU) and 7 (59.5 ± 1.5 RFU) compared to day 1 (21.3 ± 0.8 RFU) (Figure 2).
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SEM images confirmed BM-MSC attachment to L-MDF within 30 min of seeding. 
Cells appeared rounded with numerous folds and ridges and minimal surface contact 
(Figure 3A). After 1 h in culture, BM-MSCs became elongated and began spreading 
and increasing surface contact with the fibers (Figure 3B). After 1 day, imaging 
showed flattened cells with multiple adhesion points and cellular extensions as well 
as extracellular matrix (ECM) secretion (Figure 3C). By day 7 in culture, BM-MSCs 
infiltrated between fibers and demonstrated cell-to-cell interactions (Figure 3D).
Figure 3. 
Representative SEM images illustrating the morphology of cells attached to L-MDF. Following culture for 
30 min (A), 1 h (B), 1 day (C) or 7 days (D), respectively, the samples were fixed in 2.5% glutaraldehyde 
and processed for scanning electron microscopy. Images are representative of all samples evaluated and were 
taken at 3000× magnification. Scale bar represents 10 μm. Images were pseudo-colored in Adobe Photoshop to 
distinguish the cells (in yellow) from the fibers.
Figure 2. 
Proliferation of BM-MSCs attached to L-MDF over 7 days. The average relative fluorescence unit (RFU) 
values for each set of triplicate test samples were normalized to the average RFU of the corresponding control 
group (fibers of the respective donor cultured without cells) for all six donors. Asterisks represent statistically 
significant differences from day 1 proliferation activity.
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3.3  L-MDF contains important growth factors and demonstrates new bone 
formation in vivo
The ELISA results indicated the presence of growth factors in L-MDF. The 
average BMP-2 and 7 concentrations in the samples fibers were 11.24 ± 1.49 and 
85.78 ± 6.84 ng/g, respectively (Figure 4).
Additionally, in the athymic mouse muscle pouch model, histological analysis 
revealed new bone elements around and within the implanted scaffold at time of 
sacrifice (5 weeks; Figure 5). Panel A shows a set of merged images that illustrate 
Figure 4. 
BMP-2 and BMP-7 content in L-MDF. L-MDF produced from six different donors were digested in collagenase 
for 16–18 h. Using ELISAs, the resulting digestion solutions were tested for BMP-2 and BMP-7 content in 
triplicate (mean ∓ SE).
Figure 5. 
H&E staining of explants from an athymic nude mouse implanted with L-MDF (*). Merged set of H&E 
images showing new bone elements present in the entire explant at 35 days post-implantation (4× objective). 
Expanded areas show the presence of new bone elements such as cartilage (^), chondroblasts/cytes (#), bone 
marrow ($), new blood vessels (&), and new bone (+) around L-MDF implant (*) at 35 days.
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new bone elements present in the explant (4× objective). Panels B and C highlight 
the presence of new bone elements such as cartilage, chondroblasts/cytes, bone 
marrow, new blood vessels, and new bone.
4. Discussion
Demineralized bone matrices (DBMs) are widely used in spinal, orthopedic, 
craniomaxillofacial, and dental procedures to treat bone voids. An ideal DBM 
provides both osteoinductive and osteoconductive properties to promote new 
bone formation and provide a scaffold upon which cells can attach and proliferate. 
Furthermore, DBMs should be malleable and resist graft migration once impacted 
into a bone defect. To achieve these characteristics important for bone healing, 
manufacturers use a variety of techniques to process and sterilize DBMs. Despite 
demineralization being a well-known technique, the proportion of the osteoinduc-
tive element—the demineralized bone—of clinically available DBM-based graft 
materials varies widely by manufacturer. Differences in carrier material and steril-
ization may also contribute to variability among these grafts. The moldable demin-
eralized fibers described here represent a recently developed allograft configuration 
that can function as an independent bone void filler without the need of a synthetic 
carrier. This study was conducted to ensure L-MDF possess the necessary qualities 
to function in this capacity.
An osteoinductive bone graft has the ability to induce bone growth. Factors such 
as residual calcium level and growth factor content play important roles in a DBM’s 
ability to grow bone. In particular, residual calcium level can serve as an indicator 
for the availability of growth factors necessary for bone formation. The literature 
suggests that DBMs with different degrees of residual calcium show significant 
differences in osteoinductivity. Zhang et al. evaluated the effects of varying degrees 
of demineralization, particle size, donor age, and gender on the osteoinductivity 
of DBM in vivo (athymic mouse model) and in vitro (alkaline phosphatase assay) 
[22]. The authors suggested that demineralized bone with a residual calcium level 
of approximately 2% is “optimally osteoinductive”. Similarly, Turonis et al. found 
that a 2% residual calcium level in human demineralized freeze-dried bone allograft 
appears to enhance osseous wound healing [23]. The L-MDF samples discussed in 
this chapter were demineralized using a proprietary and patented process targeted 
at achieving an optimized level of residual calcium of 1–4%. Furthermore, the 
presence of specific proteins in DBM is frequently associated with its osteoinductive 
potential as growth factors can provide signals that direct cellular behavior [18, 22, 
24]. In particular, BMP-2 and 7 are important for bone growth as they are known for 
their “ability to stimulate differentiation of MSCs to osteochondroblastic lineage” 
[18]. Previous studies have reported a wide span of BMP-2 and BMP-7 levels in 
demineralized bone, with ranges from 6.5 to 110 and 44 to 125 ng/g demineralized 
bone, respectively. In this study, ELISA results indicated the presence of BMP-2 and 
7 in L-MDF (11.24 ± 1.49 and 85.78 ± 6.84 ng/g) consistent with values reported 
in the literature. This milieu of growth factors illustrate that L-MDF contain the 
appropriate trophic factor profile necessary for bone formation and are consistent 
with expected physiological levels.
The osteoinductive and osteoconductive potential of DBMs are commonly 
evaluated using an in vivo athymic mouse intramuscular pouch model to histologi-
cally assess new bone formation [25].
In the study described here, histological analysis revealed the presence of new 
bone elements demonstrating the osteoinductive potential of L-MDF. In addition, 
newly formed blood vessels were observed, which can also be indicative of the 
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osteoconductive nature of the bone graft in providing a conducive environment for 
new bone formation. The surface characteristics of DBMs play an important role in 
their ability to provide a scaffold for new bone formation [19, 20]. Bone cells need a 
hospitable environment in which to attach and thrive. In particular, increased sur-
face area, a rough topography, and interconnected networks are known to promote 
cellular attachment and cell spreading [26]. As demonstrated by the SEM imaging 
presented here, the long, interconnected L-MDF create a hospitable environment 
for BM-MSCs to infiltrate and make cell-to-cell connections. The ability of cells 
not only to quickly attach to the matrix but also maintain a healthy morphology 
throughout the duration of culture provides evidence of the osteoconductive quali-
ties of L-MDF.
The need for versatile handling has led to the addition of various inert carriers 
in commercial DBMs. However, studies have shown that carriers may negatively 
affect the inherent properties of a DBM. In particular, Lee et al. concluded that 
Poloxamer 407-based hydrogel may inhibit MSC osteoblastic differentiation by 
filling up spaces between DBM powders, negatively affecting the release of growth 
factors [21]. In a rat calvarial defect model, investigators found that the two types 
of DBM had significant differences in bone regeneration, which was attributed 
to the type of carrier [27]. Furthermore, varying the ratio of carrier to DBM can 
alter handling characteristics such as malleability and resistance to graft migration. 
Through in vivo and in vitro analyses, studies have found that increased bone con-
tent in DBMs produces larger amounts of new bone formation [25, 28, 29]. With 
this is mind, L-MDF were produced by proprietary CNC-milling cortical bone to 
create specially designed rough surfaces allowing fibers to interlock, allowing this 
bone void filler to be carrier-free. The roughness also provides numerous attach-
ment points for the cells and their lamellipodia, encouraging a flattened morphol-
ogy. These interlocking fibers thereby encourage malleability, graft placement in 
the implant site, and resistance to irrigation, all of which represent ideal handling 
characteristics.
Finally, terminal sterilization is a processing measure used to ensure the safety 
of DBMs by reducing the risk of disease transmission. This is in contrast to aseptic 
processing alone, which introduces no additional bioburden from the environment 
but alone does not guarantee sterile tissue [30, 31]. Unlike aseptic-only processed 
tissue, terminal sterilization can result in a graft with a defined sterility assurance 
level (SAL). For example, an SAL of 10−6 indicates a 1 out of 1,000,000 chance that 
a viable organism exists within any single graft [31]. Although gamma irradiation is 
currently the most common method for terminally sterilizing allografts, some reports 
suggests that gamma irradiation can negatively impact the inherent properties of 
DBMs. There are several factors to consider when evaluating the effects of gamma 
irradiation on DBMs such as dose and temperature. Irradiation performed in a high 
dose range or at uncontrolled temperatures can result in denaturing of the osteoin-
ductive signaling proteins, rendering them inactive, and/or structural damage to the 
collagen matrix due to generation of reactive oxygen species. Weintroub and Reddi 
evaluated DBM samples which were irradiated on ice at varying doses [32]. Histologic 
analysis showed DBM irradiated at 0.5–2.5 Mrad were similar to the non-irradiated 
control, indicating no effect on the induction properties of the implant. In another 
study, investigators found that DBM irradiated on dry ice (−72°C) demonstrated new 
bone formation comparable to non-irradiated samples [33]. These results demon-
strate DBMs irradiated at low dose and low temperatures are expected to retain 
properties important to clinical performance. Thus, L-MDF are terminally sterilized 
to an SAL of 10−6 using low-dose, ultra-low temperature gamma irradiation to avoid 
negative impacts to the osteoinductive and osteoconductive potential, as verified by 
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5. Conclusion
L-MDF were engineered with the ideal characteristics of a DBM in mind. The 
cortical bone fibers are demineralized to target optimal levels of residual calcium 
to yield tissue with osteoinductive potential, and also terminally sterilized to 
minimize the risk of disease transmission. The results presented here demonstrate 
that L-MDF exhibit the osteoinductive potential and osteoconductive properties 
desirable to promote bone formation while also being easy to handle for surgical 
procedures. These characteristics suggest that L-MDF are a suitable option to treat 
bone defects in a number of orthopedic, spinal, trauma, craniomaxillofacial, and 
dental applications.
Acknowledgements
We would like to acknowledge Breanne Gjurich PhD, Evans Wralstad, Alana 
Sampson MS, Yao Akpamagbo MS, and Davorka Softic MS for their contributions to 
study design, analysis and interpretation of data presented in the chapter.
Conflicts of interest
JBM, NC, PS, and MM are employees of LifeNet Health, a nonprofit 
organization.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
11
Cell Attachment and Osteoinductive Properties of Tissue Engineered, Demineralized Bone Fibers…
DOI: http://dx.doi.org/10.5772/intechopen.88290
References
[1] Khan WS, Rayan F, Dhinsa BS, Marsh 
D. An osteoconductive, osteoinductive, 
and osteogenic tissue-engineered 
product for trauma and orthopaedic 
surgery: How far are we? Stem Cells 
International. 2012;2012:236231
[2] Wang W, Yeung KWK. Bone grafts 
and biomaterials substitutes for bone 
defect repair: A review. Bioactive 
Materials. 2017;2(4):224-247
[3] Oommen AT, Krishnamoorthy VP, 
Poonnoose PM, Korula RJ. Fate of bone 
grafting for acetabular defects in total 
hip replacement. Indian Journal of 
Orthopaedics. 2015;49(2):181-186
[4] Younger EM, Chapman MW. 
Morbidity at bone graft donor sites. 
Journal of Orthopaedic Trauma. 
1989;3(3):192-195
[5] Park SB, Chung CK. Strategies of 
spinal fusion on osteoporotic spine. 
Journal of Korean Neurosurgical 
Association. 2011;49(6):317-322
[6] Lobb DC, DeGeorge BR Jr, Chhabra 
AB. Bone graft substitutes: Current 
concepts and future expectations. 
The Journal of Hand Surgery. 
2019;44(6):497-505.e2
[7] Klifto CS, Gandi SD, Sapienza A. 
Bone graft options in upper-extremity 
surgery. The Journal of Hand Surgery. 
2018;43(8):755-761.e2
[8] Fernandez de Grado G, Keller L, 
Idoux-Gillet Y, Wagner Q , Musset A-M, 
Benkirane-Jessel N, et al. Bone substitutes: 
A review of their characteristics, clinical 
use, and perspectives for large bone 
defects management. Journal of Tissue 
Engineering. 2018;9:1-18
[9] Burkus JK, Sandhu HS, Gornet MF. 
Influence of rhBMP-2 on the healing 
patterns associated with allograft 
interbody constructs in comparison 
with autograft. Spine (Phila Pa 1976). 
2006;31(7):775-781
[10] McClellan JW, Mulconrey DS, 
Forbes RJ, Fullmer N. Vertebral 
bone resorption after transforaminal 
lumbar interbody fusion with bone 
morphogenetic protein (rhBMP-2). 
Journal of Spinal Disorders and 
Techniques. 2006;19(7):483-486
[11] Lewandrowski KU, Nanson C, 
Calderon R. Vertebral osteolysis after 
posterior interbody lumbar fusion 
with recombinant human bone 
morphogenetic protein 2: A report 
of five cases. The Spine Journal. 
2007;7(5):609-614
[12] James CDT. Sir William Macewen. 
Proceedings of the Royal Society of 
Medicine. 1974;67(4):237-242
[13] de Boer HH. The history of bone 
grafts. Clinical Orthopaedics and 
Related Research. 1988;226:292-298
[14] Zimmermann G, Moghaddam A. 
Allograft bone matrix versus synthetic 
bone graft substitutes. Injury. 
2011;42:S16-S21
[15] Miller LE, Block JE. Safety and 
effectiveness of bone allografts in 
anterior cervical discectomy and 
fusion surgery. Spine (Phila Pa 1976). 
2011;36(24):2045-2050
[16] Senn N. On the healing of aseptic 
bone cavities by implantation of anti-
septic decalcified bone. The American 
Journal of the Medical Sciences. 
1889;98:219-243
[17] Urist MR, Strates BS. The classic: 
Bone morphogenetic protein. Clinical 
Orthopaedics and Related Research. 
2009;467(12):3051-3062
[18] Lieberman JR, Daluiski A, 
Einhorn TA. The role of growth factors 
Bone Grafts
12
in the repair of bone. Biology and 
clinical applications. The Journal of 
Bone and Joint Surgery. American 
Volume. 2002;84(6):1032-1044
[19] Karageorgiou V, Kaplan D. 
Porosity of 3D biomaterial scaffolds 
and osteogenesis. Biomaterials. 
2005;26(27):5474-5491
[20] Rodriguez RU, Kemper N, 
Breathwaite E, Dutta SM, Hsu EL, 
Hsu WK, et al. Demineralized bone 
matrix fibers formable as general and 
custom 3D printed mold-based implants 
for promoting bone regeneration. 
Biofabrication. 2016;8(3):035007
[21] Lee JH, Baek HR, Lee KM, Lee HK, 
Im SB, Kim YS, et al. The effect of 
poloxamer 407-based hydrogel on the 
osteoinductivity of demineralized bone 
matrix. Clinics in Orthopedic Surgery. 
2014;6(4):455-461
[22] Zhang M, Powers RM Jr, 
Wolfinbarger L Jr. Effect(s) of the 
demineralization process on the 
osteoinductivity of demineralized bone 
matrix. Journal of Periodontology. 
1997;68(11):1085-1092
[23] Turonis JW, McPherson JC 3rd, 
Cuenin MF, Hokett SD, Peacock ME, 
Sharawy M. The effect of residual 
calcium in decalcified freeze-dried 
bone allograft in a critical-sized defect 
in the Rattus norvegicus calvarium. 
The Journal of Oral Implantology. 
2006;32(2):55-62
[24] Wolfinbarger L, Eisenlohr LM, 
Ruth K. Demineralized bone matrix: 
Maximizing new bone formation 
for successful bone implantation. In: 
Pietrzak WS, editor. Musculoskeletal 
Tissue Regeneration: Biological 
Materials and Methods. Totowa, NJ: 
Humana Press; 2008. pp. 93-117
[25] Boyan BD, Ranly DM, McMillan J, 
Sunwoo M, Roche K, Schwartz Z. 
Osteoinductive ability of human 
allograft formulations. Journal of 
Periodontology. 2006;77(9):1555-1563
[26] Murphy MB, Suzuki RK, Sand TT, 
Chaput CD, Gregory CA. Short term 
culture of human mesenchymal stem 
cells with commercial osteoconductive 
carriers provides unique insights into 
biocompatibility. Journal of Clinical 
Medicine. 2013;2(3):49-66
[27] Tavakol S, Khoshzaban A, 
Azami M, Kashani IR, Tavakol H, 
Yazdanifar M, et al. The effect of 
carrier type on bone regeneration of 
demineralized bone matrix in vivo. 
The Journal of Craniofacial Surgery. 
2013;24(6):2135-2140
[28] Han B, Tang B, Nimni ME. 
Quantitative and sensitive in vitro 
assay for osteoinductive activity 
of demineralized bone matrix. 
Journal of Orthopaedic Research. 
2003;21(4):648-654
[29] Atti E, Abjornson C, Diegmann M, 
Zhang K, Cammisa FP, Myers ER. High 
resolution X-ray computed tomography 
as a technique to study osteoinductivity 
of demineralized bone matrix. The 
Spine Journal. 2003;3(5):120
[30] Vangsness CT Jr, Wagner PP, 
Moore TM, Roberts MR. Overview of 
safety issues concerning the preparation 
and processing of soft-tissue 
allografts. Arthroscopy: The Journal 
of Arthroscopic and Related Surgery: 
Official Publication of the Arthroscopy 
Association of North America and the 
International Arthroscopy Association. 
2006;22(12):1351-1358
[31] Vangsness CT Jr, Garcia IA, Mills 
CR, Kainer MA, Roberts MR, Moore 
TM. Allograft transplantation in the 
knee: Tissue regulation, procurement, 
processing, and sterilization. The 
American Journal of Sports Medicine. 
2003;31(3):474-481
13
Cell Attachment and Osteoinductive Properties of Tissue Engineered, Demineralized Bone Fibers…
DOI: http://dx.doi.org/10.5772/intechopen.88290
[32] Wientroub S, Reddi AH. Influence 
of irradiation on the osteoinductive 
potential of demineralized bone 
matrix. Calcified Tissue International. 
1988;42(4):255-260
[33] Dziedzic-Goclawska A, Ostrowski 
K, Stachowicz W, Michalik J, Grzesik W. 
Effect of radiation sterilization on the 
osteoinductive properties and the rate of 
remodeling of bone implants preserved 
by lyophilization and deep-freezing. 
Clinical Orthopaedics and Related 
Research. 1991;272:30-37
